Cheapest Humira Alternative to Be Sold via Mark Cuban’s Drug Company

 

• Yusimry to launch in July, cost $995 for two autoinjectors
• Biosimilar to be sold via Mark Cuban’s Cost Plus Drugs Company

AbbVie Inc.’s blockbuster drug Humira costs the US health system $90,000 per patient each year. Now, an emerging competitor plans to sell an alternative at an 85% discount. 

Coherus BioSciences Inc. will launch the cheapest-ever Humira copycat, Yusimry, in July, with a list price of $995 for two autoinjectors, the company said Thursday. That’s far below the $6,922 AbbVie charges for the same supply of its drug used to treat rheumatoid arthritis, plaque psoriasis and other autoimmune conditions.

https://www.bloomberg.com/news/articles/2023-06-01/cheapest-humira-alternative-to-be-sold-by-mark-cuban-s-cost-plus-drugs